comprehensive -WSS

comprehensive

author：entertainment 2025-10-08 15:28:01 - browse：9986

Alnylam headquarters — Kristoffer Tripplaar/Sipa USA/AP

The Food and Drug Administration rejected an Alnylam Pharmaceuticals’ therapy for an increasingly prevalent heart disease, the company said Monday, citing insufficient evidence that the treatment meaningfully improved patients’ lives.

Alnylam will no longer seek approval of its drug, an intravenous medicine sold as Onpattro, for people with ATTR-CM, a progressive disease that leads to heart failure if left untreated. The company is in the late stages of development of an updated version of Onpattro that can be administered through a small needle under the skin. Data from a pivotal study, expected next year, would support an FDA application for that treatment.

For Onpattro, a 12-month clinical trial found that the treatment outperformed placebo on a test of how far patients could walk over the course of six minutes, suggesting the medicine slowed down the progression of ATTR-CM. Onpattro also improved patients’ scores on a quality-of-life questionnaire compared to placebo.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： Lab trade group sues FDA to halt regulation of lab

explore

WSS

Pancreatic cancer early detection could be helped by AI

AI used to predict Covid

Readout Newsletter: Moderna bird flu vaccine, Biohaven, ASCO

Biogen walks away from Aduhelm, years after polarizing approval

Humana’s losses in Medicare Advantage tank its stock

Adam's Biotech Scorecard: Do Sarepta's exon

knowledge

comprehensive

entertainment

Peter Hotez and the public health issue of online harassment

Readout Newsletter: The latest on Novavax, Merck, Bluebird

Peter Hotez and the public health issue of online harassment

Adam's Biotech Scorecard: Do Sarepta's exon

State Dept. review finds Biden bears some blame for Afghanistan failures

Health Care Service Corp to buy Cigna Medicare Advantage plans

New air purifier tech could be key to improving indoor air quality

iTeos Therapeutics debuts first data on TIGIT

ChatGPT in medicine: STAT answers readers' burning questions

Readout Newsletter: CG Oncology IPO, Eli Lilly, Tesla, Merck

leisure time

Stigma and the return of syphilis

AI used to predict Covid

Bernie Sanders is gearing up to subpoena pharma CEOs

Zyn nicotine pouches become unlikely player in latest culture war

Health insurers say they are turning to AI to cut costs, improve care

Startling documents reveal new facets of Sacklers' opioid empire

knowledge

explore

leisure time

focus